“We rate HZNP as 12-month price target of $21. We continue to believe the rare/orphan disease and rheumatology businesses are underappreciated. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $21. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $21.”
According to TipRanks.com, Chen is a 4-star analyst with an average return of 8.1% and a 42.8% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Melinta Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Horizon Pharma Inc with a $23.29 average price target, which is a 22.8% upside from current levels. In a report issued on October 1, Mizuho Securities also maintained a Buy rating on the stock with a $25 price target.
Based on Horizon Pharma Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $32.84 million. In comparison, last year the company had a GAAP net loss of $63.97 million.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Horizon Pharma Plc engages in the research, development and market of pharmaceutical products. The medicines intend to treat arthritis, inflammation and orphan diseases. It distributes its products under the brands such as Actimmune, Buphenyl, Duexis, Krystexxa, Migergot, Pennsaid, Ravicti, Rayos and Vimovo.